Review: Creutzfeldt-Jakob disease: Prion protein type, disease phenotype and agent strain

Neuropathology and Applied Neurobiology

Volumn 38, Issue 4, 2012, Pages 296-310

  Head, M W ^a   Ironside, J W ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Agent strain; Creutzfeldt Jakob disease; Neuropathology; Prion protein; PRNP gene; Protein misfolding disease

Indexed keywords

PRION PROTEIN;

CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MOLECULAR GENETICS; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PHYSICAL CHEMISTRY; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; CREUTZFELDT-JAKOB SYNDROME; HUMANS; PHENOTYPE; PRIONS;

EID: 84860910331     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2012.01265.x     Document Type: Review

References (97)

1. Aguzzi A, Kana V. An introduction to prion disorders. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2nd edn. Eds DW Dickson, RO Weller. Chichester: Wiley-Blackwell, 2012; 315-21.
2. Ironside J, Ghetti B, Head MW, Piccardo P, Will RG. Prion diseases. In Greenfiled's Neuropathology 8th edn. Eds S Love, DN Louis, DW Ellison. London: Hodder Arnold, 2008; 1197-273.
3. Budka H, Head MW, Ironside JW, Gambetti P, Parchi P, Tagliavini F. Sporadic Creutzfeld-Jakob disease. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2nd edn. Eds DW Dickson, RO Weller. Chichester: Wiley-Blackwell, 2012; 322-35.
4. Parchi P, Gambetti P, Capellari S. Genetic Creutzfeldt-Jakob disease. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2nd edn. Eds DW Dickson, RO Weller. Chichester: Wiley-Blackwell, 2012; 336-45.
5. Ironside JW, Knight RSG, Head MW. Iatrogenic Creutzfeldt-Jakob disease. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2nd edn. Eds DW Dickson, RO Weller. Chichester: Wiley-Blackwell, 2012; 381-6.
6. Ironside JW, Head MW, Will RG. Variant Creutzfeldt-Jakob disease. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2nd edn. Eds DW Dickson, RO Weller. Chichester: Wiley-Blackwell, 2012; 354-63.
7. McLean CA. Kuru. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2nd edn. Eds DW Dickson, RO Weller. Chichester: Wiley-Blackwell, 2012; 378-80.
8. Ghetti B, Tagliavini F, Kovacs G, Piccardo P. Gerstmann-Straussler-Scheinker disease. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2nd edn. Eds DW Dickson, RO Weller. Chichester: Wiley-Blackwell, 2012; 364-77.
9. Parchi P, Capellari P, Gambetti P. Fatal familial and sporadic insomnia. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2nd edn. Eds DW Dickson, RO Weller. Chichester: Wiley-Blackwell, 2012; 346-9.
10. Ghetti B, Piccardo P, Spillantini MG, Ichimiya Y, Porro M, Perini F, Kitamoto T, Tateishi J, Seiler C, Frangione B, Bugiani O, Giaccone G, Prelli F, Goedert M, Dlouhy SR, Tagliavini F. Vascular variant of prion protein cerebral amyloidosis with τ-positive tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci U S A 1996; 93: 744-8.
11. Peden AH, Head MW, Ritchie DR, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-9.
12. Ironside JW, Bishop MT, Connolly K, Hegazy D, Lowrie S, Le Grice M, Ritchie DL, McCardle LM, Hilton DA. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 2006; 332: 1186-8.
13. Kaski D, Mead S, Hyare H, Cooper S, Jampana R, Overell J, Knight R, Collinge J, Rudge P. Variant CJD in an individual heterozygous for PRNP codon 129. Lancet 2009; 374: 2128.
14. Peden A, McCardle L, Head MW, Love S, Ward HJT, Cousins SN, Keeling DM, Millar CM, Hill FGH, Ironside JW. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
15. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterisation. Br Med Bull 2003; 66: 213-39.
16. Mastrianni J, Nixon R, Layzer R, Telling GC, Han D, DeArmond SJ, Prusiner SJ. Prion protein conformation in a patient with sporadic fatal insomnia. N Engl J Med 1999; 340: 1630-8.
17. Zou WQ, Puoti G, Xiao X, Yuan J, Qing L, Cali I, Shimoji M, Langeveld JPM, Castellani R, Notary S, Crain B, Schmidt RE, Geschwind M, DeArmond SJ, Cairns NJ, Dickson D, Honig L, Torres JM, Mastrianni J, Capellari S, Giaccone G, Belay ED, Schonberger LB, Cohen M, Perry G, Kong Q, Parchi P, Tagliavini F, Gambetti P. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol 2010; 68: 162-72.
18. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136-44.
19. Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998; 95: 13363-83.
20. Nicoll AJ, Collinge J. Preventing prion pathogenicity by targeting the cellular prion protein. Infect Disord Drug Targets 2009; 9: 48-57.
21. Orru C, Caughey B. Prion seeded conversion and amplification assays. Top Curr Chem 2011; 305: 121-33.
22. Colby D, Prusiner SB. De novo generation of prion strains. Nat Rev Microbiol 2011; 9: 771-7.
23. Bruce M. TSE strain variation. Br Med Bull 2003; 66: 99-108.
24. Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol 1994; 68: 7859-68.
25. Monari L, Chen SG, Brown P, Parchi P, Petersen RB, Mikol J, Gray F, Cortelli P, Montagna M, Ghetti B, Goldfarb LG, Gajdusek DC, Lugaresi E, Gambetti P, Autilio-Gambetti L. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism. Proc Natl Acad Sci U S A 1994; 91: 2839-42.
26. Tagliavini F, Prelli F, Ghiso J, Bugiani O, Serban D, Prusiner SB, Farlow MR, Ghetti B, Frangione B. Amyloid protein of Gerstmann-Straussler-Scheinker disease (Indiana kindred) is an 11kD fragment of prion protein with an N-terminal glycine at codon 58. EMBO J 1991; 10: 513-19.
27. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383: 685-90.
28. Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, Gabizon R, Mastrianni J, Lugaresi E, Gambetti P, Prusiner SB. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 1996; 274: 2079-82.
29. Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, Farlow M, Dickson DW, Sima AA, Trojanowski JQ, Petersen RB, Gambetti P. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996; 39: 767-78.
30. Parchi P, Capellari S, Chen SG, Petersen RB, Gambetti P, Kopp N, Brown P, Kitamoto T, Tateishi J, Giese A, Kretzschmar H. Typing prion isoforms. Nature 1997; 386: 232-4.
31. Parchi P, Zou W, Wang W, Brown P, Capellari S, Ghetti B, Kopp N, Schulz-Schaeffer WJ, Kretzschmar HA, Head MW, Ironside JW, Gambetti P, Chen SG. Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci U S A 2000; 97: 10168-72.
32. Parchi P, Cescatti M, Notari S, Schulz-Schaeffer WJ, Capellari S, Giese S, Zou WQ, Kretschmar H, Ghetti B, Brown P. Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease. Brain 2010; 133: 3030-42.
33. Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S, Lineham JM, Brandner S, Wadsworth JDF, Hewitt P, Collinge J. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006; 368: 2061-7.
34. Head MW, Yull HM, Ritchie DL, Bishop MT, Ironside JW. Pathological investigation of the first blood donor and recipient pair linked by transfusion-associated variant Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol 2009; 35: 433-6.
35. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichenberger N, Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46: 224-33.
36. Sc typing in Creutzfeldt-Jakob disease: a Western blot study within the NeuroPrion consortium. Brain Pathol 2009; 19: 384-91.
37. Sc in the same brain. Neurology 1999; 53: 2173-6.
38. Cali I, Castellani R, Alshekhlee A, Cohen Y, Blevins J, Yuan J, Langeveld JPM, Parchi P, Safar JG, Zou WQ, Gambetti P. Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on the phenotype and prion-type characteristics. Brain 2009; 132: 2643-58.
39. Sc types: an updated classification. Acta Neuropathol 2009; 118: 659-71.
40. Sc types in individuals with Creutzfeldt-Jakob disease. Lancet Neurol 2005; 4: 805-14.
41. Yull H, Ritchie DL, Langeveld JP, van Zijderveld FG, Bruce ME, Ironside JW, Head MW. Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease. Am J Pathol 2006; 168: 151-7.
42. res in sporadic Creutzfeldt-Jakob disease MM1. Am J Pathol 2011; 178: 1309-15.
43. Head MW, Ironside JW. Sporadic Creutzfeldt-Jakob disease: discrete subtypes or a spectrum of disease? Brain 2009; 132: 2627-9.
44. Head MW, Bunn TJR, Bishop MT, McLoughlin V, Lowrie S, McKimmie CS, Williams MC, McCardle L, MacKenzie J, Knight R, Will RG, Ironside JW. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob diseases: UK cases 1991-2002. Ann Neurol 2004; 55: 851-9.
45. Head MW, Ritchie D, Smith N, McLoughlin V, Nailon W, Samad S, Masson S, Bishop M, McCardle L, Ironside JW. Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an immunocytochemical, quantitative and biochemical study. Am J Pathol 2004; 164: 143-53.
46. Brandel JP, Heath CA, Head MW, Levavasseur E, Knight R, Laplanche JL, Langeveld JPM, Ironside JW, Hauw JJ, Mackenzie J, Alperovitch A, Will RG, Haik S. Variant Creutzfeldt-Jakob disease in France and the United Kingdom: evidence for the same agent strain. Ann Neurol 2009; 65: 249-56.
47. Notari S, Moleres F, Hunter SB, Belay ED, Schonberger LB, Cali I, Parchi P, Shieh WJ, Brown P, Zaki S, Zou WQ, Gambetti P. Multiorgan detection and characterisation of protease-resistant prion protein in a case of variant CJD examined in the United States. PLoS ONE 2010; 5: e8765.
48. Yuan J, Xiao X, McGeehan J, Dong Z, Cali I, Fujioka H, Kong Q, Kneale G, Gambetti P, Zou WQ. Insoluble aggregates and protease-resistant conformers of prion protein in uninfected human brains. J Biol Chem 2006; 281: 34848-58.
49. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 2010; 33: 317-25.
50. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions and prionoids. Neuron 2009; 64: 783-90.
51. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. Inclusion formation and neuronal death through neuron-to-neuron transmission of α-synuclein. Proc Natl Acad Sci U S A 2009; 106: 13010-15.
52. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A 2009; 106: 12571-2.
53. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2010; 11: 155-9.
54. Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci 2010; 123: 1191-201.
55. Munch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neural cells. Proc Natl Acad Sci U S A 2011; 108: 3548-53.
56. Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell 2011; 147: 498-508.
57. Walker LC, LeVine H, Mattson MP, Jucker M. Inducible proteopathies. Trends Neurosci 2006; 29: 438-43.
58. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Matthews PM, Ghiso G, Staufenbiel M, Walker LC, Jucker M. Exongenous induction of cerebral β-amyloidogenesis is governed by host and agent. Science 2006; 313: 1781-4.
59. Westermark GT, Westermark P. Prion-like aggregates: infectious agents in human disease. Trends Mol Med 2010; 16: 501-7.
60. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. De novo induction of amyloid-β deposition in vivo. Mol Psychiatry 2011. DOI: 10.1038/mp.2011.120 [Epub ahead of print].
61. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997; 389: 498-501.
62. Ritchie DL, Boyle A, McConnell I, Head MW, Ironside JW, Bruce ME. Transmission of variant Creutzfeldt-Jakob disease from brain and lymphoreticular tissue show uniform and conserved bovine spongiform encephalopathy-related phenotypic properties on primary and secondary passage in wild-type mice. J Gen Virol 2009; 90: 3075-82.
63. Bishop MT, Hart P, Aitchison L, Baybutt HN, Plinston C, Thomson V, Tuzi NL, Head MW, Ironside JW, Will RG, Manson JC. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 2006; 5: 393-8.
64. Bishop MT, Will RG, Manson JC. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci U S A 2010; 107: 12005-10.
65. Lasmezas CI, Deslys JP, Demaimay R, Adjou KT, Lamoury F, Dormond D, Robain O, Ironside J, Hauw JJ. BSE transmission to macaques. Nature 1996; 381: 743-4.
66. Brown DA, Bruce ME, Frazer JR. Comparison of the neuropathological characteristics of bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD) in mice. Neuropathol Appl Neurobiol 2003; 29: 262-72.
67. Hill AF, Desbroulais M, Joiner S, Sidle KCL, Gowland I, Collinge J. The same prion strain causes vCJD and BSE. Nature 1997; 389: 448-50.
68. Scott MR, Will R, Ironside J, Nguyen HOB, Tremblay P, DeArmond SJ, Prusiner SB. Compelling transgenic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci U S A 1999; 96: 15137-42.
69. Lasmezas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, Fournier JG, Haw JJ, Rossier J, Dormond D. Transmission of the BSE agent in the absence of detectable abnormal prion protein. Science 1997; 275: 402-5.
70. Asano M, Mohri S, Ironside JW, Ito M, Tamaoki N, Kitamoto T. vCJD prions acquire altered virulence through trans-species infection. Biochem Biophys Res Commun 2006; 342: 293-9.
71. Padilla D, Beringue V, Espinosa JC, Andreoletti O, Juamain E, Reine F, Herzog L, Gutierrez-Adam A, Pintado B, Laude H, Torres JM. Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. PLoS Pathog 2011; 7: e1001319.
72. Plinston C, Hart P, Chong A, Hunter N, Foster J, Piccardo P, Manson JC, Barron RM. Increased susceptibility of human-PrP transgenic mice to bovine spongiform encephalopathy infection following passage in sheep. J Virol 2011; 85: 1174-81.
73. Asante EA, Lineham JM, Desbroulais M, Joiner S, Gowland I, Wood AL, Welch J, Hill AF, Lloyd SE, Wadsworth JDF, Collinge J. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J 2002; 21: 6358-66.
74. Giles K, Glidden DV, Patel S, Korth C, Groth D, Lemus A, DeArmond SJ, Prusiner SB. Human prion strain selection in transgenic mice. Ann Neurol 2010; 68: 151-61.
75. Wadsworth JDF, Asante EA, Desbroulais JM, Joiner S, Gowland I, Welsh J, Stone L, Lloyd SE, Hill AF, Brandner S, Collinge J. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 2004; 306: 1793-6.
76. Asante EA, Lineham JM, Gowland I, Joiner S, Fox K, Cooper S, Osiguwa O, Gorry M, Welsh J, Houghton R, Desbroulais M, Brandner S, Wadsworth JDF, Collinge J. Dislocation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proc Natl Acad Sci U S A 2006; 103: 10759-64.
77. Bishop MT, Ritchie DR, Will RG, Ironside JW, Head MW, Thomson V, Bruce M, Manson JC. No major change in vCJD agent strain after secondary transmission via blood transfusion. PLoS ONE 2008; 3: e2878.
78. Beringue V, Le Dur A, Tixador P, Reine F, Lepurry L, Perret-Liaudet A, Haik S, Vilotte JL, Fontes M, Laude H. Prominent and persistent extraneural infection in human PrP transgenic mice infected with variant CJD. PLoS ONE 2008; 1: e1419.
79. Yull H, Ironside JW, Head MW. Further characterisation of the prion protein molecular types detectable in the NIBSC Creutzfeldt-Jakob disease brain reference materials. Biologicals 2009; 37: 210-15.
80. Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science 2007; 318: 930-6.
81. Beringue V, Herzog L, Jaumain E, Reine F, Sibille P, Le Dur A, Vilotte JL, Laude H. Facilitated cross-species transmission of prions in extraneural tissues. Science 2012; 335: 472-5.
82. Collinge J. The risk of prion zoonoses. Science 2012; 335: 411-13.
83. Balkema-Buschman A, Ziegler U, McIntyre L, Keller M, Hoffman C, Rogers R, Hills B, Groschup MH. Experimental challenge of cattle with German atypical bovine spongiform encephalopathy (BSE) isolates. J Toxicol Environ Health 2011; 74: 103-9.
84. Beringue V, Herzog L, Reine F, Le Dur A, Casalone C, Vilotte JL, Laude H. Transmission of atypical bovine prions to mice transgenic for human prion protein. Emerg Infect Dis 2008; 14: 1898-901.
85. Lasmezas CI, Fournier JG, Nouvel V, Boe H, Marce D, Lamoury F, Kopp N, Hauw JJ, Ironside J, Bruce M, Dormond D, Deslys JP. Adaptation of bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob disease: implications for human health. Proc Natl Acad Sci U S A 2001; 98: 4142-7.
86. Korth C, Kaneko K, Groth D, Heye N, Telling G, Mastrianni J, Parchi P, Gambetti P, Will R, Ironside J, Heinrich C, Tremblay P, DeArmond SJ, Prusiner SB. Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene. Proc Natl Acad Sci U S A 2003; 100: 4784-9.
87. Taguchi Y, Mohri S, Ironside JW, Muramoto T, Kitamoto T. Humanized knock-in mice expressing chimeric prion protein showed varied susceptibility to different human prions. Am J Pathol 2003; 163: 2585-93.
88. Scott MR, Peretz D, Nguyen HOB, DeArmond SJ, Prusiner SB. Transmission barriers for bovine, ovine, and human prions in transgenic mice. J Virol 2005; 79: 5259-71.
89. Nonno R, Di Bari MA, Cardone F, Vaccari G, Fazzi P, Dell'Omo G, Cartoni C, Ingrosso L, Boyle A, Galeno R, Sbriccoli M, Lipp HP, Bruce M, Pocchiari M, Agrimi U. Efficient transmission and characterisation of Creutzfeldt-Jakob disease strains in bank voles. PLoS Pathog 2006; 2: e12.
90. Williams L, Brown P, Ironside J, Gibson S, Will R, Ritchie D, Kreil TR, Abee C. Clinical, neuropathological and immunohistochemical features of sporadic and variant forms of Creutzfeldt-Jakob disease in the squirrel monkey (Saimiri sciureus). J Gen Virol 2007; 88: 688-95.
91. Wadsworth JDF, Joiner S, Lineham JM, Desbruslais M, Fox K, Cooper S, Cronier S, Asante EA, Mead S, Brandner S, Hill AF, Collinge J. Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc Natl Acad Sci U S A 2008; 105: 3885-90.
92. Safar JG, Giles K, Lessard P, Letessier F, Patel S, Serban A, DeArmond SJ, Prusiner SB. Conserved properties of human and bovine strains on transmission to guinea pigs. Lab Invest 2011; 91: 1326-36.
93. Sc type and PRNP genotype in an in-vitro conversion assay. Neuroreport 2008; 19: 1783-6.
94. res type 1/type 2 dichotomy in Creutzfeldt-Jakob disease. PLoS Pathog 2008; 4: 1000026.
95. Scin vivo. J Biol Chem 2007; 282: 35878-86.
96. Picardo P, Manson JC, King D, Ghetti B, Barron RM. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci U S A 2007; 104: 4712-17.
97. Kobayashi A, Sakuma N, Matsuura Y, Mohri S, Aguzzi A, Kitamoto T. Experimental verification of the traceback phenomenon in prion infection. J Virol 2010; 84: 3230-8.